Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Donepezil effects on language in children with Down syndrome: results of the first 22-week pilot clinical trial.

Literature DB >> 15378553

Donepezil effects on language in children with Down syndrome: results of the first 22-week pilot clinical trial.

James H Heller, Gail A Spiridigliozzi, P Murali Doraiswamy, Jennifer A Sullivan, Bythe G Crissman, Priya S Kishnani.

Abstract

Entities: Chemical Species

Mesh：

Substances：

Year: 2004 PMID： 15378553 PMCID： PMC2665884 DOI： 10.1002/ajmg.a.30184

Source DB: PubMed Journal: Am J Med Genet A ISSN： 1552-4825 Impact factor: 2.802

× No keyword cloud information.

3 in total

1. Cholinergic therapy for Down's syndrome.

Authors: P S Kishnani; J A Sullivan; B K Walter; G A Spiridigliozzi; P M Doraiswamy; K R Krishnan
Journal: Lancet Date: 1999-03-27 Impact factor: 79.321

2. Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate.

Authors: Michael G Chez; Mary Aimonovitch; Thomas Buchanan; Susan Mrazek; Ryan J Tremb
Journal: J Child Neurol Date: 2004-03 Impact factor: 1.987

3. Donepezil for the treatment of language deficits in adults with Down syndrome: a preliminary 24-week open trial.

Authors: James H Heller; Gail A Spiridigliozzi; Jennifer A Sullivan; P Murali Doraiswamy; Ranga R Krishnan; Priya S Kishnani
Journal: Am J Med Genet A Date: 2003-01-15 Impact factor: 2.802

3 in total

12 in total

1. Safety and efficacy of rivastigmine in adolescents with Down syndrome: long-term follow-up.

Authors: James H Heller; Gail A Spiridigliozzi; Blythe G Crissman; Jane Anne McKillop; Haru Yamamoto; Priya S Kishnani
Journal: J Child Adolesc Psychopharmacol Date: 2010-12 Impact factor: 2.576

2. Safety and efficacy of rivastigmine in adolescents with Down syndrome: a preliminary 20-week, open-label study.

Authors: James H Heller; Gail A Spiridigliozzi; Blythe G Crissman; Jennifer A Sullivan; Rebecca L Eells; Jennifer S Li; P Murali Doraiswamy; K Ranga Krishnan; Priya S Kishnani
Journal: J Child Adolesc Psychopharmacol Date: 2006-12 Impact factor: 2.576

Review 3. Relevance of donepezil in enhancing learning and memory in special populations: a review of the literature.

Authors: J Helen Yoo; Maria G Valdovinos; Dean C Williams
Journal: J Autism Dev Disord Date: 2007-01-13

4. Maternal choline supplementation differentially alters the basal forebrain cholinergic system of young-adult Ts65Dn and disomic mice.

Authors: Christy M Kelley; Brian E Powers; Ramon Velazquez; Jessica A Ash; Stephen D Ginsberg; Barbara J Strupp; Elliott J Mufson
Journal: J Comp Neurol Date: 2014-04-15 Impact factor: 3.215

5. Parental Perspectives on Pharmacological Clinical Trials: a Qualitative Study in Down Syndrome and Fragile X Syndrome.

Authors: Victoria Reines; Krista Charen; Tracie Rosser; Arri Eisen; Stephanie L Sherman; Jeannie Visootsak
Journal: J Genet Couns Date: 2017-05-24 Impact factor: 2.537

Donepezil effects on language in children with Down syndrome: results of the first 22-week pilot clinical trial.

1. Cholinergic therapy for Down's syndrome.

2. Treating autistic spectrum disorders in children: utility of the cholinesterase inhibitor rivastigmine tartrate.

3. Donepezil for the treatment of language deficits in adults with Down syndrome: a preliminary 24-week open trial.

1. Safety and efficacy of rivastigmine in adolescents with Down syndrome: long-term follow-up.

2. Safety and efficacy of rivastigmine in adolescents with Down syndrome: a preliminary 20-week, open-label study.

Review 3. Relevance of donepezil in enhancing learning and memory in special populations: a review of the literature.

4. Maternal choline supplementation differentially alters the basal forebrain cholinergic system of young-adult Ts65Dn and disomic mice.

5. Parental Perspectives on Pharmacological Clinical Trials: a Qualitative Study in Down Syndrome and Fragile X Syndrome.

6. A 'cure' for Down syndrome: what do parents want?

Review 7. Developing interventions for cancer-related cognitive dysfunction in childhood cancer survivors.

Review 8. Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities.

Review 9. Donepezil for dementia in people with Down syndrome.

10. Down syndrome and the molecular pathogenesis resulting from trisomy of human chromosome 21.